top of page
Innovative Drug Safety Evaluation
With Primate In Vitro Models
10X
Accelerate Timelines: Early determination of toxicologic effects can speed up drug selection by 10x
25X
Cost Savings: Exir Bio in vitro testing is 1/25th the cost of an in vivo nonhuman primates (NHP) study
17X
Reduce Animal Use: The cost of using NHPs in biomedical research has increased 17X since 2019
“America has shortage of lab monkeys”
The Economist
Exir Bio’s primate in vitro models enhance drug safety evaluations while aligning with the FDA Modernization Act 2.0 and 3.0, as well as the principles of the 3R’s (Replace, Reduce, and Refine animal use).
Bridging the Translational Gap
Case Study
"There is increasing guidance from regulatory authorities to adopt New Approach Methodologies for drug efficacy and safety assessment that reduce the use of animals in drug development. Exir Bio's expertise and proprietary technology in NHP iPSC adeptly position the company to fulfill the mandate of these organizations"
- Director of Preclinical Safety at a major Pharma company
© 2025 Exir Bio. All Rights Reserved.
bottom of page